Autoimmune diseases and fillers: what to assess
Patients with autoimmune disease often come to the orofacial harmonization (HOF) practice: lupus, rheumatoid arthritis, thyroiditis, psoriasis, inflammatory bowel disease and others are common, often well controlled for years. The question "can I have a filler?" has no ready-made answer. It depends on the disease, the phase, the medications, the product and the area.
This page lays out what to assess, at a review level. It complements general contraindications in HOF, which has the broad list, and does not replace the product's package insert or the opinion of the physician who follows the patient. The choice of product, plan and timing is a decision for the qualified professional, according to the rules of their professional council.
Why does autoimmune disease change the assessment?
Fillers are foreign materials to the body, even if biocompatible. In people whose immune system is dysregulated or modulated by medication, three things can change:
- Inflammatory response to the product. The literature describes late reactions, such as recurrent swelling and inflammatory nodules, sometimes triggered by infection or vaccination. See late swelling after hyaluronic acid.
- Risk of infection. Immunosuppressants, systemic corticosteroids and biologics raise the risk and can hide the signs of infection in the first days.
- The skin and tissue affected by the disease itself. Some diseases directly affect the face, such as the skin lesions of lupus, skin hardening in scleroderma and localized atrophy in forms of morphea.
Active or controlled disease: what is the difference in practice?
This is the first question to answer, and it does not depend on your examination: it depends on medical follow-up.
| Situation | Usual approach described | What to record |
|---|---|---|
| Disease active or in a flare | Postpone the elective procedure | Reason for postponing and guidance given |
| Controlled disease, no immunosuppression | Individual assessment, with input from the treating physician | Length of control, medications, physician's opinion |
| Controlled disease on an immunosuppressant or biologic | Individual assessment and timing aligned with the physician | Name of the drug and date of the last dose or infusion |
| High-dose or recent systemic corticosteroid | In general, postpone until reassessment | Dose and period |
| Diagnosis with no current follow-up | Refer for reassessment before deciding | Referral made |
Hypothetical example: a patient with rheumatoid arthritis controlled for two years, on a biologic, wants to fill the nasolabial fold. Before deciding, the professional asks the patient for a note from the rheumatologist about disease control and the best timing relative to the drug administration, records it in the patient file and only then discusses the plan.
What should you ask in the medical history?
The medical history of the autoimmune patient needs to go beyond "do you have any disease?". See the general outline in medical history in HOF and add:
- What the diagnosis is, for how long, and who follows the patient.
- When the last flare was and how it showed up.
- A complete list of medications, including corticosteroids, immunosuppressants, biologics and antimalarials.
- Recent infections and recent or scheduled vaccines.
- A previous reaction to a filler, botulinum toxin or another implant.
- Photosensitivity and skin lesions on the face.
- Raynaud phenomenon, which indicates a change in microcirculation.
Which diseases call for specific attention?
| Condition | Points of attention in the face |
|---|---|
| Lupus erythematosus (systemic or cutaneous) | Facial skin lesions, photosensitivity, use of immunosuppressants and corticosteroids |
| Rheumatoid arthritis | Immunosuppressants and biologics, risk of infection |
| Scleroderma and morphea | Hardened, poorly distensible skin; there are reports of correcting contour defects in stable disease, always with a joint assessment |
| Graves disease | Eye involvement changes the assessment of the periorbital area and under-eye area |
| Psoriasis and inflammatory bowel disease | Frequent use of biologics |
| Dermatomyositis | Skin changes and photosensitivity |
| Myasthenia gravis and other neuromuscular junction diseases | Important context for botulinum toxin, whose package inserts carry specific warnings |
These notes are general. Each patient has their own combination of disease activity, affected organs and treatment.
What about adjuvant-induced syndrome?
Since 2011, the literature has described the hypothesis of an autoimmune or inflammatory syndrome induced by adjuvants, which links some implanted materials, such as silicone and certain fillers, to immune conditions in predisposed people. It is a controversial topic: most of the evidence comes from reports and case series, and there is no established causal link for the most widely used resorbable fillers.
What remains for practice is caution. In a patient with autoimmune disease, permanent materials such as PMMA tend to be avoided in the review literature, because a late reaction cannot be reversed. With hyaluronic acid, hyaluronidase offers a path to reversal, which should be on hand. With collagen biostimulators there is no antidote, which weighs on the choice.
What about botulinum toxin in the autoimmune patient?
Botulinum toxin is not an implant and does not stay in the tissue like a filler, so the concern about a late inflammatory reaction is different. The central point is diseases that affect transmission between nerve and muscle, such as myasthenia gravis: the package inserts carry specific warnings for them, and the decision goes through the neurologist who follows the patient. It is also worth recording medications that may interact with the toxin, according to the product's package insert. See botulinum toxin: fundamentals.
Which complications deserve monitoring?
- Late and recurrent swelling, sometimes weeks or months later.
- Inflammatory nodules and granuloma. See nodules after a biostimulator.
- Infection and biofilm, with signs that the immunosuppressant may blunt. See infection and biofilm after filler.
- Hypersensitivity reaction to the product or to hyaluronidase.
- Worsening of a skin lesion at the site, in diseases with skin involvement.
How should you document and talk to the patient?
The informed consent of the autoimmune patient should state the disease, the medications, the increased risk of late reaction and infection, and what was agreed with the treating physician. If the decision is not to treat or to postpone, document that too, and consider the procedure refusal form when the patient insists against your advice.
Keep the product lot number, the photos and the treating physician's information in the patient record. If a reaction appears months later, these details make a difference in management.
What about Harmy?
Checklist before filling an autoimmune patient
- Diagnosis, disease duration and treating physician recorded.
- Disease confirmed as controlled, with no recent flare.
- Complete list of medications, with the date of the last immunosuppressant or biologic dose.
- Recent infections and vaccines checked.
- Product package insert read regarding autoimmune diseases.
- Preference for a reversible material considered; hyaluronidase available with hyaluronic acid.
- Specific consent covering the risk of late reaction and infection.
- Staged plan and follow-up scheduled.
- Contact channel and warning signs explained in writing. See post-procedure instructions.
Frequently asked questions
Can someone with lupus have facial harmonization?
There is no single answer. Active disease is usually a reason to postpone, and many filler package inserts list autoimmune diseases among contraindications or precautions. With the disease under control, the decision is individual, after an assessment with the physician who follows the patient and a reading of the product's package insert.
Can a filler trigger an autoimmune disease?
There are reports of late inflammatory reactions and a hypothesis described in the literature, autoimmune syndrome induced by adjuvants, which links some implanted materials to immune conditions. It is a debated topic, with no established causal link for most fillers, which is why it belongs in the consent as a risk to explain.
Can someone on an immunosuppressant have a filler?
The immunosuppressant raises the risk of infection and can mask its signs. The decision depends on the medication, the phase of the disease and the guidance of the treating physician, who should be consulted before any elective procedure.
Does an autoimmune thyroid disease rule out fillers?
Not necessarily, but Graves disease with eye involvement changes the assessment of the periorbital area, and thyroid changes can cause swelling that confuses the evaluation. Confirm disease control with the physician who follows the patient.
Harmy images are illustrative simulations generated by AI from the patient's photo to support the conversation between practitioner and patient. They are not a promise of results. Indication, technique, product and volume are solely the decision of the licensed practitioner. This content is for information only and does not replace a clinical assessment.